{
    "nct_id": "NCT03583255",
    "official_title": "A Combination Therapy for Cancer-Related Fatigue in Advanced Cancer Patients",
    "inclusion_criteria": "* Diagnosis of locally advanced cancer (defined as metastatic or recurrent cancer or completed 2 lines of therapy) with fatigue >= 4/10 (0-10 scale) on the Edmonton Symptom Assessment Scale (ESAS)\n* Presence of fatigue for at least 2 weeks\n* Normal cognition defined as Memorial Delirium Assessment Scale (MDAS) of =< 13/30 completed in person or via video conference\n* Hemoglobin > 8 g/L within 2 weeks of enrollment in the study\n* Zubrod performance status =< 2\n* Life expectancy of >= 4 months\n* Able to read, write, and speak English\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with a history of hypersensitivity to dexamethasone or having any contraindication to physical activity as determined by the treating physician\n* Reports of a fall in the past 30 days\n* Uncontrolled diabetes mellitus as defined by a random blood sugar of > 200 mg/dl not being monitored by their primary care physician\n* Sepsis and/or acute, chronic, or ongoing infections that are currently being treated with systemic antimicrobials\n* Current, active peptic ulcer disease\n* Neutropenia as defined by an absolute neutrophil count (ANC) of < 1000 cells/mm\n* Regular participation in moderate- or vigorous-intensity physical activity for >= 30 minutes at least 5 times a week and strength training for >= 2 days\n* Symptomatic cardiac disease (New York Heart Association functional class III or IV) or coronary artery disease\n* Patients currently on immunotherapy\n* Inability to comply with study protocol procedures",
    "miscellaneous_criteria": ""
}